Metagenomi Therapeutics (MGX) Other Accumulated Expenses (2024 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Other Accumulated Expenses of $228000.0 for Q1 2026, up 94.87% year-over-year from $117000.0 in Q1 2025, and up 38.18% quarter-over-quarter from $165000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Other Accumulated Expenses (2024 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Other Accumulated Expenses for 3 consecutive years, with $228000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 94.87% year-over-year to $228000.0; the TTM figure through Mar 2026 stood at $228000.0 (up 94.87% YoY), while the FY2025 annual figure was $165000.0, down 63.0% from the prior year.
- Other Accumulated Expenses improved to $228000.0 in Q1 2026 per MGX's latest filing, from $165000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $446000.0 in Q4 2024 and bottomed at $117000.0 in Q1 2025.
- Historically, Other Accumulated Expenses has averaged $257333.3 across 3 years, with a median of $252000.0 in 2025.
- Annual changes were most pronounced in 2025 — Other Accumulated Expenses slumped 63.0% — and 2026, when it jumped 94.87%.
- Metagenomi Therapeutics' Other Accumulated Expenses stood at $446000.0 in 2024, then sank by 63.0% to $165000.0 in 2025, then surged by 38.18% to $228000.0 in 2026.
- Business Quant data shows MGX's Other Accumulated Expenses at $228000.0 in Q1 2026, $165000.0 in Q4 2025, and $312000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 232,000.00 |
| Mar 31, 2026 | 228,000.00 |
| Dec 31, 2025 | 165,000.00 |
| Sep 30, 2025 | 312,000.00 |
| Jun 30, 2025 | 276,000.00 |
| Mar 31, 2025 | 117,000.00 |
| Dec 31, 2024 | 446,000.00 |